Sugentech, a global in vitro diagnostics company, has built Korea's largest allergy testing solution, covering 239 allergens.

Sugentech Establishes Allergy Testing Solution Covering 239 Allergens View original image

Sugentech announced on October 29 that it had obtained domestic regulatory approval for its new allergy diagnostic product, 'SGTi-Allergy PLUS 120.'


The newly approved product can offer tests for up to 239 allergens when used alongside the existing 'SGTi-Allergy Screen PLUS.' It can test for a wide range of allergy triggers encountered in Korea and abroad, including inhalant, environmental, and food allergens. Analysis of 45 component allergens also allows for more detailed assessment of allergy sensitization.


Building on this, Sugentech plans to target the European market. The company is pursuing CE certification under the European Union's In Vitro Diagnostic Medical Devices Regulation (IVDR) and expects to obtain approval by the end of this year. It plans to use this as a springboard to register its products in major European countries and expand its local distribution network, strengthening its export competitiveness in the global allergy diagnostics market.



A Sugentech official said, "This approval for our new product will be an important opportunity to expand our allergy diagnostics business, backed by Korea's broadest testing range of 239 allergens and our in-house expertise in developing equipment and reagents. We will expand supply to major domestic reference laboratories and large hospitals, and accelerate global business growth in 2027 by leveraging our experience in overseas markets, including Asia and Africa, and obtaining IVDR approval in Europe by the end of this year."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing